Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | LPL | P06858 | 13/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25203373 | 0.84 | CSF1R (0.48) | CSF1RLPLLIPGCA1CA2 | |
| SCHEMBL1877988 | 0.84 | CSF1R (0.48) | CSF1RLPLLIPGCA1CA2 | |
| SCHEMBL15969034 | 0.83 | AAK1 (0.40) | CSF1RLPLLIPGCA1CA2 | |
| SCHEMBL1130429 | 0.83 | LPL (0.41) | CSF1RLPLLIPGAAK1EGFR | |
| SCHEMBL2415783 | 0.83 | LPL (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL7852757 | 0.82 | ALDH1A1 (0.39) | — | |
| SCHEMBL13858234 | 0.82 | HTR2A (0.45) | CSF1RLPLLIPGCA1CA2 | |
| SCHEMBL2412403 | 0.81 | LPL (0.41) | CSF1RLPLLIPGCA1CA2 | |
| SCHEMBL29524907 | 0.81 | LPL (0.41) | CSF1RLPLLIPGCA1CA2 | |
| SCHEMBL178289 | 0.81 | CSF1R (0.49) | CSF1RLPLLIPGCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115630-A1 | METAL COMPLEXES | UDC IRELAND LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-12180233-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-12-31 | — | — | US | disclosed |
| CN-111699192-B | Metal complex | UDC爱尔兰有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-3752512-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2023-03-01 | — | — | EP | disclosed |
| US-20220289778-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2022-09-15 | — | — | US | disclosed |
| EP-3601304-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3752512-A1 | METAL COMPLEXES | Merck Patent GmbH (DE) | 2020-12-23 | — | — | EP | disclosed |
| EP-3601304-A1 | METAL COMPLEXES | Merck Patent GmbH (DE) | 2020-02-05 | — | — | EP | disclosed |
| CN-110461859-A | Metal complex | MERCK PATENT GMBH | 2019-11-15 | — | — | CN | disclosed |
| WO-2019158453-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-08-22 | — | — | WO | disclosed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1506190-B1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | HOFFMANN LA ROCHE (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-7005432-B2 | Substituted imidazol-pyridazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1606268-A1 | HETEROCYCLIC KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1506190-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003097637-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12180233-B2 | Metal complexes | IMMT, MCU, SOD1 | CSF1R 3953/4885LPL 3959/4885LIPG 3702/4885 |
| US-20250115630-A1 | METAL COMPLEXES | IMMT, MCU, SOD1 | CSF1R 3953/4885LPL 3959/4885LIPG 3702/4885 |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CSF1R 2559/4885LPL 4075/4885LIPG 2157/4885 |
| US-20220289778-A1 | METAL COMPLEXES | IMMT, MCU, SOD1 | CSF1R 3953/4885LPL 3959/4885LIPG 3702/4885 |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | GRIN2B, GRIN2A, GRIN2C | CSF1R 838/4885LPL 4626/4885LIPG 4808/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | CSF1R 3275/4885LPL 3517/4885LIPG 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.